8-K: Celularity Inc. Announces Strong Biomaterials Revenue and Product Pipeline Update

Celularity Inc. reports strong revenue from biomaterial products and provides an update on its product pipeline and regulatory filings.

Summary

• Celularity Inc. expects to report over $24 million in net revenue from biomaterial products for the first half of 2024.
• The company anticipates over $9 million in net revenue from the recently acquired Rebound product.
• These figures are preliminary and unaudited, and may change as the financial review for the quarters ending June 30, 2024, September 30, 2024, and December 31, 2024, is ongoing.
• Celularity is developing several new products including Celularity Tendon Wrap, Celularity Bone Void Filler, and Celularity Placental Matrix.
• The company expects to submit a 510(k) notification for Celularity Tendon Wrap in early 2025, for FUSE Bone Void Filler in the second half of 2025, and for Celularity Placental Matrix in 2026.
• Celularity is also developing Celularity Placental Dermal Filler Matrix as a Class III medical device, requiring a premarket approval application (PMA) to the FDA.
• The company reaffirms its guidance for combined net sales of its advanced biomaterial product and biobanking businesses to be in the range of $50 million to $56 million.

Sentiment

Score: 7

Explanation: The document conveys a positive outlook with strong revenue figures and a clear product pipeline. However, the ongoing compliance issues and the preliminary nature of the financial results temper the overall sentiment.

Positives

• The company's biomaterial product revenue is strong, with over $24 million expected for the first half of 2024.
• The acquisition of Rebound is contributing significantly to revenue, with over $9 million in sales anticipated.
• Celularity is actively developing a pipeline of new products with clear regulatory pathways.
• The company has received preliminary product classifications from the FDA for its new products.
• The company has reaffirmed its revenue guidance for the year.
• The company has successfully filed its annual report on Form 10-K for fiscal year 2023 and its quarterly report on Form 10-Q for the first quarter 2024.

Negatives

• The financial results are preliminary and unaudited, and may be subject to change.
• The company is still working to regain full compliance with Nasdaq's listing requirements.
• The company has not yet finalized its financial results for the three months and six months ended June 30, 2024, or the third and fourth quarters ended September 30, 2024, and December 31, 2024, respectively.

Risks

• The company's liquidity situation and stock price volatility are potential risks.
• There are inherent risks in biotechnological development and the regulatory approval process.
• The company's actual results could differ materially from forward-looking statements due to various factors.
• The company is subject to risks outlined in its annual report on Form 10-K filed with the SEC.

Future Outlook

Celularity expects continued growth in its biomaterials business and is focused on advancing its product pipeline. The company has reaffirmed its guidance for combined net sales of its advanced biomaterial product and biobanking businesses to be in the range of $50 million to $56 million.

Management Comments

• Robert J. Hariri, MD, PhD, stated that the company is resolutely committed to regaining full compliance with Nasdaq's listing requirements.
• Robert J. Hariri, MD, PhD, expressed confidence in the company's plan to expand its advanced biomaterial products business.
• Robert J. Hariri, MD, PhD, stated that the company is focused on the long-term opportunities to create meaningful shareholder value.

Industry Context

This announcement highlights the growing market for regenerative and cellular medicine, particularly in the area of advanced biomaterials. The acquisition of Rebound and the development of new placental-derived products position Celularity to capitalize on this trend. The company's focus on obtaining regulatory approvals and expanding its product portfolio is consistent with industry best practices.

Comparison to Industry Standards

• Companies like Organogenesis and MiMedx also focus on advanced wound care and regenerative medicine using biomaterials, and their revenue figures are often used as benchmarks for Celularity.
• The development of placental-derived products is a growing trend, with companies like AmnioTech also active in this space, making Celularity's product pipeline comparable to these competitors.
• The regulatory pathway for Celularity's products, particularly the 510(k) submissions, is a common approach in the medical device industry, similar to companies like Integra LifeSciences.
• Celularity's revenue guidance of $50-$56 million is a key metric to compare against the revenue of similar-sized companies in the regenerative medicine space.

Stakeholder Impact

• Shareholders are informed of the company's progress and future plans.
• Employees are working to execute the company's growth strategy.
• Customers will benefit from the company's expanding product portfolio.
• Suppliers will be impacted by the company's increased production and sales.
• Creditors will be interested in the company's financial performance and future prospects.

Next Steps

• Celularity intends to file its Form 10-Q for the second quarter 2024 within the coming weeks.
• The company plans to submit a 510(k) notification for Celularity Tendon Wrap in early 2025.
• The company plans to submit a 510(k) notification for FUSE Bone Void Filler in the second half of 2025.
• The company plans to submit a 510(k) notification for Celularity Placental Matrix in 2026.
• Celularity will continue to execute its plan to expand its advanced biomaterial products business.

Key Dates

Keywords

biomaterials, regenerative medicine, cellular medicine, placental-derived, FDA, 510(k), HCPCS, revenue, product pipeline, regulatory filings